GlaxoSmithKline will unveil data about its latest diabetes drug today, said Bloomberg News.
That medication is part of the reason behind a hostile takeover by Human Genome Sciences, which is trying to purchase Glaxo for $2.6 billion.
Read more at Bloomberg.